These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26371722)

  • 1. Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use.
    de Denus S; Dubé MP; Tardif JC
    Expert Opin Pharmacother; 2015; 16(17):2549-52. PubMed ID: 26371722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.
    Bottorff MB; Bright DR; Kisor DF
    Pharmacotherapy; 2017 Sep; 37(9):1005-1013. PubMed ID: 28654154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors: back to prime time?
    Gupta M; Verma S; Mancini GB
    Heart; 2007 Sep; 93(9):1015-6. PubMed ID: 17699166
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.
    Berinstein E; Levy A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics in Cardiovascular Medicine.
    Weeke PE
    Adv Pharmacol; 2018; 83():333-360. PubMed ID: 29801582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of cardiovascular drugs.
    Saleh A; Al-Abcha A; Pereira N
    Curr Opin Cardiol; 2023 May; 38(3):207-214. PubMed ID: 37016993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
    Božina N; Vrkić Kirhmajer M; Šimičević L; Ganoci L; Mirošević Skvrce N; Klarica Domjanović I; Merćep I
    Croat Med J; 2020 Apr; 61(2):147-158. PubMed ID: 32378381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.
    Dubé MP; de Denus S; Tardif JC
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):59-64. PubMed ID: 26768480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
    Terra SG; Johnson JA
    Am J Cardiovasc Drugs; 2002; 2(5):287-96. PubMed ID: 14727958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PHARMACOGENOMIC DETERMINANTS OF RESPONSE TO CARDIOVASCULAR DRUGS.
    Stankov KM; Stanimirov BG; Mikov MM
    Med Pregl; 2015; 68(7-8):259-65. PubMed ID: 26591639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
    Kaufman AL; Spitz J; Jacobs M; Sorrentino M; Yuen S; Danahey K; Saner D; Klein TE; Altman RB; Ratain MJ; O'Donnell PH
    Mayo Clin Proc; 2015 Jun; 90(6):716-29. PubMed ID: 26046407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009.
    Joseph PG; Pare G; Ross S; Roberts R; Anand SS
    Clin Cardiol; 2014 Jan; 37(1):48-56. PubMed ID: 24105892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Implementation of Cardiovascular Pharmacogenomics.
    Pereira NL; Stewart AK
    Mayo Clin Proc; 2015 Jun; 90(6):701-4. PubMed ID: 26046404
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular pharmacogenomics and individualized drug therapy.
    Pereira NL; Weinshilboum RM
    Nat Rev Cardiol; 2009 Oct; 6(10):632-8. PubMed ID: 19707183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision Medicine, Cardiovascular Disease and Hunting Elephants.
    Joyner MJ
    Prog Cardiovasc Dis; 2016; 58(6):651-60. PubMed ID: 26902518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of cardiovascular medicine: victims of our own success?
    Vardas PE
    Hellenic J Cardiol; 2013; 54(2):155-6. PubMed ID: 23557621
    [No Abstract]   [Full Text] [Related]  

  • 19. The Daniel K. Inouye College of Pharmacy Scripts: Precision Medicine Through the Use of Pharmacogenomics: Current Status and Barriers to Implementation.
    Ciarleglio AE; Ma C
    Hawaii J Med Public Health; 2017 Sep; 76(9):265-269. PubMed ID: 28900583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
    Roden DM; Van Driest SL; Wells QS; Mosley JD; Denny JC; Peterson JF
    Circ Res; 2018 Apr; 122(9):1176-1190. PubMed ID: 29700066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.